



ZIKAVAX PARTNERSHIP

Today's Catalyst For Tomorrow's Vaccines

Dr Odile LEROY DCVMN Seoul 26th September 2017

Product Development Partnership

THE EUROPEAN VACCINE INITIATIVE IS A PRODUCT DEVELOPMENT PARTNERSHIP WHICH AIMS TO ACCELERATE THE DEVELOPMENT OF VACCINES FOR DISEASES OF POVERTY





PDPs

Adapted from IAVI 2013



To contribute to the global efforts to control diseases of poverty by supporting development and clinical assessment of vaccines for diseases of poverty



Support translational vaccine R&D with focus on preclinical to early clinical development

Operational, managerial and financial support




Support capacity strengthening in low-income target regions



Bringing together and aligning stakeholders




Initiatives Address the Entire Pipeline




Supp

Support in Vaccine Development



Support in Vaccine Development

EVI






How is EVI addressing the global need for new vaccines?

- Feed the pipeline FIRST! PDP
- Coordination connecting the chain
- Harmonisation guidelines, procedures
- Building European infrastructure with global network
 TRANSVAC2 project 1st call 15/10/2017

Public-Private Partnership for Product Development



CONFIDENTIAL

Partnership Principles and Strategy for Success

- To involve affected population and their policy makers in strategy for development plan et setting priorities (diseases, products):
 - objectives developed together
- ✓ product development (including analysis of the results (both safety and efficacy) AND
- capacity building infrastructure and training) Need to call funding agencies to have a global portfolio management (as for malaria, tb and hiv vaccine) for PRND assessing gaps and defining priorities
- To call funding agencies to have a global portfolio management assessing gaps and defining priorities
 - global portfolio management AND
 - connecting the chain

Partnership Principles and Strategy for Success

- To have **sustainable pipeline** populated with enough candidate to increase chance of success
- To advocate for pooled funding mechanisms with FRESH funding to manage global portfolios.
 - ✓ Funders should explicitly include product development aspect into their funding mechanism, as well as the requirement for the applicants to outline their access policies.

ZIKAVAX Fast track development of a Zika vaccine based on measles vector

Duration: 48 months

Total grant: €4,918,137.50





EC-funded project under H2020



EUROPEAN VACCINE INITIATIVE

DE LA RECHERCHE À L'INDUSTRIE





- 1. To construct and characterise recombinant MV expressing Zika virus proteins as soluble secreted antigens
- 2. To demonstrate preclinical immunogenicity and protective efficacy of the recombinant MV-Zika vaccine candidate(s) in a mouse model and in a non-human primate (NHP) model of Zika virus infection
- 3. To manufacture a good manufacturing practice (GMP) clinical lot of the MV-Zika vaccine candidate using scalable platform technology
- 4. To assess the safety and immunogenicity of the MV-Zika vaccine candidate in a phase I dose-escalation clinical trial




ZIKAVAX Methodology

- Delivery platform technology: measles vaccine vector (live attenuated)
 - demonstrated proof of principle in clinical and pre-clinical studies.
- Rapid adaptability and effectiveness for a variety of pathogens (Chikungunya virus, West Nile virus, Ebola, *Plasmodium*, *Mycobacterium*)
- Optimised manufacturing process
- ➢ high yields and purity using standards equipment → <u>Rapid transfer to</u> <u>other manufacturers for any outbreak</u>
- Ultimate objective is the demonstration of safety and immunogenicity in adults in a Phase 1 clinical trial

Technology platform: Measles Vector

Inventor: Dr Frederic Tangy – Institut Pasteur (France)

Development: Themis Bio (Austria)



MV genes are indicated: N (nucleoprotein), PVC (phoshoprotein and V/C proteins), M (matrix), F (fusion), H (hemagluttinin), L (polymerase), T7 (T7 RNA polymerase promoter), hh (hammerhead ribozyme), T7t (T7 RNA polymerase terminator), ∂ (hepatitis delta virus ribozyme), red arrows (additional transcription units).







WHO **DRAFT** Target Product Profile:

A vaccine to protect against congenital Zika virus syndrome in neonates, for use during an emergency

Joachim Hombach, Initiative for Vaccine Research, WHO on behalf of the WHO PDVAC ZIKV vaccine working group




6th June 2016





Vaccine Pipeline : ~ 50 projects from 27 institutions/organisations



~ 10 vaccine in phase I/II clinical trial


- 5 inactivated whole virus vaccines
- 5 live attenuated whole virus vaccines
- 11 recombinant sub-unit non VLP/VLP
- 11 recombinant viral vector vaccine
- 4 DNA or RNA or peptide






Issues and concerns for vaccine development

Animal models



Appropriate for antiviral and vaccine studies except evaluation of interferon pathway agents

 AG129 (Aliota et al. 2016; Rossi et al., 2016; Zmurko, et al.; 2016; Julander et al., unpublished data; review by Sarathy et al. 2015 (Dengue)) A129 (IFNAR -/-) Mice Develop Neurological Disease and Succumb to Infection



Lazear Cell Host Microbe 2016

June 6, 2016 Heather Greenstone, PhD Program Officer for Small Animal Models Virology Branch Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases National Institutes of Health hgreenstone@niaid.nih.gov



National Institute of Allergy and Infectious Diseases **Issues and concerns for vaccine development**


Animal models

June 6, 2016 Heather Greenstone, PhD Program Officer for Small Animal Models Virology Branch Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases National Institutes of Health hgreenstone@niaid.nih.gov





Macaque monkeys are susceptible to infection with Zika virus



Days since Zika virus infection



Further development needed for vaccine development

- **1**. Human challenge models
- **1.** Definition and validation of correlates/surrogates of protection HARMONISATION & STANDARDISATION OF IMMUNO-ASSAYS

Further investigations needed for vaccine development

- **1**. Cross reactivity with other flavivirus
- 2. Epidemiology pattern



EVI donors

DGIS (NL) Irish Aid (IE) BMBF via KfW (DE) BMBF (DE) FP6/FP7 (EC) EDCTP (EC & EU MS) IMI-IMI2 GHIT Nobelpharma

Subjects in EVI funded clinical trials

EVI sub-contractors, CMOs, CROs, Consultants

Scientific Community

Europe, Africa, India, Japan, USA

EVI EEIG members

- Stockholm University, SE
- Heidelberg University, DE
- Royal College of Surgeon in Ireland, IE
- Jenner Vaccine Foundation-University of Oxford, UK
- Biomedical Primate Research Centre, NL
- Intravacc, NL
- Institut Pasteur, FR

Many thanks for your attention! <u>contact.us@euvaccine.eu</u> -<u>www.euvaccine.eu</u> <u>https://youtu.be/ToU9Pl4HyY4</u>



You can



Contribute to make a better world free of diseases of poverty